Yousif Capital Management LLC Sells 5,565 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Yousif Capital Management LLC trimmed its position in Vir Biotechnology, Inc. (NASDAQ:VIR) by 13.6% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 35,353 shares of the company’s stock after selling 5,565 shares during the period. Yousif Capital Management LLC’s holdings in Vir Biotechnology were worth $356,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Maryland State Retirement & Pension System lifted its holdings in Vir Biotechnology by 6.4% during the third quarter. Maryland State Retirement & Pension System now owns 31,647 shares of the company’s stock worth $297,000 after acquiring an additional 1,894 shares during the period. Bank of New York Mellon Corp lifted its holdings in Vir Biotechnology by 2.9% during the third quarter. Bank of New York Mellon Corp now owns 861,484 shares of the company’s stock worth $8,072,000 after acquiring an additional 24,492 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Vir Biotechnology by 28.3% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,343 shares of the company’s stock worth $181,000 after acquiring an additional 4,261 shares during the period. Strs Ohio lifted its holdings in Vir Biotechnology by 24.7% during the third quarter. Strs Ohio now owns 46,000 shares of the company’s stock worth $431,000 after acquiring an additional 9,100 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Vir Biotechnology by 6.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 57,706 shares of the company’s stock worth $541,000 after acquiring an additional 3,628 shares during the period. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Insider Activity at Vir Biotechnology

In related news, CEO Backer Marianne De sold 72,995 shares of the business’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $9.46, for a total transaction of $690,532.70. Following the sale, the chief executive officer now directly owns 678,457 shares in the company, valued at approximately $6,418,203.22. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CFO Sung Lee sold 6,008 shares of the business’s stock in a transaction dated Wednesday, March 27th. The stock was sold at an average price of $9.89, for a total transaction of $59,419.12. Following the completion of the transaction, the chief financial officer now directly owns 100,492 shares in the company, valued at $993,865.88. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Backer Marianne De sold 72,995 shares of the business’s stock in a transaction dated Wednesday, April 3rd. The stock was sold at an average price of $9.46, for a total value of $690,532.70. Following the transaction, the chief executive officer now owns 678,457 shares of the company’s stock, valued at $6,418,203.22. The disclosure for this sale can be found here. In the last three months, insiders have sold 152,831 shares of company stock worth $1,525,844. 15.60% of the stock is owned by company insiders.

Vir Biotechnology Price Performance

Shares of VIR opened at $10.22 on Tuesday. The firm has a market cap of $1.37 billion, a PE ratio of -2.55 and a beta of 0.47. The stock’s fifty day moving average price is $9.79 and its two-hundred day moving average price is $9.61. Vir Biotechnology, Inc. has a 1 year low of $7.61 and a 1 year high of $27.48.

Vir Biotechnology (NASDAQ:VIR) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.51. Vir Biotechnology had a negative return on equity of 32.58% and a negative net margin of 677.69%. The company had revenue of $56.38 million for the quarter, compared to analyst estimates of $11.71 million. During the same period in the previous year, the company posted ($1.06) EPS. The firm’s revenue for the quarter was down 10.5% compared to the same quarter last year. Sell-side analysts anticipate that Vir Biotechnology, Inc. will post -4.04 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on VIR. JPMorgan Chase & Co. lifted their price target on Vir Biotechnology from $10.00 to $12.00 and gave the stock a “neutral” rating in a report on Friday. HC Wainwright reiterated a “buy” rating and set a $110.00 price target on shares of Vir Biotechnology in a report on Friday, March 15th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $15.00 price target on shares of Vir Biotechnology in a report on Friday. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $33.57.

Vir Biotechnology Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.